Quick Answer
Upstream Bio, Inc. reported Cash and Equivalents of $101.58 million for fiscal year 2025.
Upstream Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $101.58M | -68.8% |
| 2024 | $325.89M | +1161.5% |
| 2023 | $25.83M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $72.16M | +119.0% | +58.7% |
| June 30, 2025 | $45.46M | -4.0% | -36.3% |
| March 31, 2025 | $71.31M | +126.3% | -78.1% |
| December 31, 2024 | $325.89M | +1161.5% | +889.1% |
| September 30, 2024 | $32.95M | -30.4% | -30.4% |
| June 30, 2024 | $47.34M | — | +50.2% |
| March 31, 2024 | $31.51M | — | +22.0% |
| December 31, 2023 | $25.83M | — | -45.4% |
- Upstream Bio, Inc. showed a decrease of -68.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Upstream Bio, Inc.’s cash and equivalents has grown by 293.2% (from $25.83 million to $101.58 million).
- The most recent figure is from Upstream Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: